ALX Oncology (ALXO) director Chris Takimoto receives 40,400 stock options

Q: What insider transaction did ALX Oncology (ALXO) report for Chris H. Takimoto?

The company reported that director Chris H. Takimoto received a grant of 40,400 stock options on January 20, 2026 .

Q: How do the ALX Oncology (ALXO) stock options vest for Chris H. Takimoto?

The filing states that the options vest in 12 equal monthly installments beginning on February 20, 2026 .

Q: What type of security was granted to the ALX Oncology (ALXO) director?

The security is a stock option (right to buy) ALX Oncology common stock at a fixed exercise price of $1.32 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ALX Oncology Holdings director Chris H. Takimoto received a grant of stock options on January 20, 2026. The award covers 40,400 stock options with an exercise price of $1.32 per share, giving the right to buy the company’s common stock at that price in the future. The options expire on January 19, 2036, providing a long-term incentive tied to the company’s share performance.

According to the filing, the 40,400 options vest in 12 equal monthly installments beginning on February 20, 2026. After this grant, Takimoto beneficially owns 40,400 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Takimoto Chris H

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	40,400	$0.00	--

Holdings After Transaction: Stock option (right to buy) — 40,400 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/21/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Takimoto Chris H

(Last)

(First)

(Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock option (right to buy)	$1.32	01/20/2026		A		40,400		⁽¹⁾	01/19/2036	Common Stock	40,400	$0	40,400	D

Explanation of Responses:

1. Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026.

	/s/ Shelly Pinto, by power of attorney	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ALX Oncology (ALXO) report for Chris H. Takimoto?

The company reported that director Chris H. Takimoto received a grant of 40,400 stock options on January 20, 2026.

What is the exercise price of the new ALX Oncology (ALXO) stock options?

The stock options granted to Chris H. Takimoto have an exercise price of $1.32 per share for ALX Oncology common stock.

How do the ALX Oncology (ALXO) stock options vest for Chris H. Takimoto?

The filing states that the options vest in 12 equal monthly installments beginning on February 20, 2026.

When do Chris H. Takimoto’s ALX Oncology (ALXO) stock options expire?

The stock options granted on January 20, 2026 have an expiration date of January 19, 2036.

How many ALX Oncology (ALXO) derivative securities does Chris H. Takimoto own after this transaction?

After the reported grant, Chris H. Takimoto beneficially owns 40,400 derivative securities (stock options), held directly.

What type of security was granted to the ALX Oncology (ALXO) director?

The security is a stock option (right to buy) ALX Oncology common stock at a fixed exercise price of $1.32 per share.